Trials / Completed
CompletedNCT02158910
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,231 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is for investigation and collection of Aricept safety information with a dose increase on Alzheimer's disease patients.
Detailed description
This is an observational study to systematically investigate domestic patients with Alzheimer's disease to figure out the safety under a situation of the use of Donepezil HCl 23mg. Additionally, if the dose of Donepezil HCl increase, there is need to examine the safety of Donepezil HCl 23mg in depth for patients with Alzheimer's disease by comparing aspects of occurring adverse events by the type of Donepezil HCl increase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aricept | 5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2014-06-09
- Last updated
- 2017-03-07
Locations
13 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02158910. Inclusion in this directory is not an endorsement.